Ensysce Biosciences' Professor Richard Langford Selected to Speak at FDA Public Hearing on the Potential Future Therapeutic Use of Psychedelic Drugs

Richard Langford, chief medical officer of Ensysce Biosciences' newly acquired unit Cy Biopharma, has been selected to present in person at the FDA's September 14, 2026 public hearing on the potential future therapeutic use of psychedelic drugs. Langford is among a limited group of stakeholders invited to comment in the afternoon session on access considerations and best practices for data collection; the hearing supports Executive Order 14401, which directs federal agencies to accelerate research and review of psychedelic therapies for serious mental health conditions.

AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.